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Abstract
Von Willebrand factor (VWF) is a pro-hemostatic multimeric plasma protein that promotes platelet aggregation and
stabilizes coagulation factor VIII (FVIII) in plasma. The metalloproteinase ADAMTS13 regulates the platelet aggregation
function of VWF via proteolysis. Severe deficiency of ADAMTS13 is associated with thrombotic thrombocytopenic purpura,
but does not always correlate with its clinical course. Therefore, other proteases could also be important in regulating VWF
activity. In the present study, we demonstrate that VWF is cleaved by the cytotoxic lymphocyte granule component
granzyme M (GrM). GrM cleaved both denaturated and soluble plasma-derived VWF after Leu at position 276 in the D3
domain. GrM is unique in that it did not affect the multimeric size and pro-hemostatic platelet aggregation ability of VWF,
but instead destroyed the binding of VWF to FVIII in vitro. In meningococcal sepsis patients, we found increased plasma GrM
levels that positively correlated with an increased plasma VWF/FVIII ratio in vivo. We conclude that, next to its intracellular
role in triggering apoptosis, GrM also exists extracellularly in plasma where it could play a physiological role in controlling
blood coagulation by determining plasma FVIII levels via proteolytic processing of its carrier VWF.
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Introduction
Von Willebrand factor (VWF) is a pro-hemostatic multimeric
plasma protein that promotes platelet adhesion by bridging injured
subendothelium and platelet receptors [1]. In addition, VWF
tightly binds to and stabilizes coagulation factor VIII (FVIII) in
plasma, thereby protecting FVIII from proteolytic degradation
and prolonging FVIII half-life [2]. The multimeric structure of
VWF is important for multiple interactions with platelets and
endothelial components under high shear stress. Interaction with
subendothelial structures induces a conformational change of
VWF and the exposure of platelet binding domains [3]. This pro-
hemostatic activity of VWF is regulated by the metalloprotease
ADAMTS13, which specifically cleaves VWF in its A2 domain
[4]. ADAMTS13 downregulates the multimeric size of VWF in
order to prevent unwanted platelet thrombus formation. Defi-
ciency of ADAMTS13 as is present in patients with thrombotic
thrombocytopenic purpura (TTP) results in the occurrence of
microvascular platelet thrombi in different organs, demonstrating
its physiological importance [5]. However, low ADAMTS13 levels
are also observed in TTP patients in remission [6,7], not all
patients with congenital ADAMTS13 deficiency develop TTP [8],
and increased VWF proteolysis has been identified in acute TTP
patients without loss of larger multimers [9]. These findings
strongly suggest the existence of other important proteases that
regulate VWF activity, in addition to ADAMTS13. Indeed, the
VWF A2 domain has been identified as a hot spot for proteolysis
by ADAMTS13 and other (leukocyte) proteases [10,11]. Buzza
et al. have shown that VWF activity in vitro could be regulated via
cleavage by a serine protease from the granules of cytotoxic
lymphocytes, i.e. granzyme B (GrB) [12].
GrB is secreted by cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells, which are key players in eliminating tumor cells
and pathogen-infected cells [13]. Besides GrB, four other
granzymes are known in human, i.e. GrA, GrH, GrK, and
GrM, which differ on the basis of their substrate specificity [13]. In
addition to their well-established roles as intracellular effectors of
target cell death, increasing evidence has been composed that
granzymes may have extracellular roles as well. Elevated levels of
circulating GrA, GrB, and GrK occur in certain allergic responses,
rheumatoid arthritis, viral/bacterial infections, and sepsis [14–16].
GrB is also elevated in several vascular diseases such as
arthrosclerosis, where both local and plasma levels correlate with
disease severity [17,18]. GrB does not cleave soluble VWF in
plasma but cleavage is induced when VWF is unfolded or released
from activated endothelial cells under physiological shear, thereby
mimicking the action of ADAMTS13 to regulate the platelet-
adhesive function of VWF [12]. Whether other granzymes than
GrB also cleave VWF and affect VWF function remains unknown.
Whereas ADAMTS13 and GrB cleave VWF only under
denaturating conditions or physiological shear stress, we demon-
strate in the present study that GrM cleaves both denaturated and
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did not affect the multimeric size and pro-hemostatic platelet
aggregation ability of VWF, but instead destroyed the binding of
VWF to FVIII in vitro. In meningococcal sepsis patients, we found
increased plasma GrM levels that positively correlated with an
increased plasma VWF/FVIII ratio in vivo. Our data indicate for
the first time that extracellular GrM exists in plasma, where it
could play a physiological role in controlling blood coagulation by
determining plasma FVIII levels via proteolytic processing of its
carrier VWF.
Materials and Methods
Ethics Statement
Informed consent was given for each patient by the parents and
the study was approved by the local ethics committee and
performed according to local guidelines.
Materials
Plasma-derived human VWF was purified from VWF/FVIII
concentrate as described. [19] Human placenta collagen type III
was from Sigma. Recombinant human FVIII was obtained from
Baxter (Advate). Ristocetin was from DiaMed (DiaRistin,
Switzerland). The rabbit polyclonal anti-human VWF antibody
was from DAKO. Active recombinant human granzymes (GrA,
GrB, GrH, GrK and GrM) and inactive granzyme mutants (SA-
variants) were expressed in Pichia pastoris and purified by cation-
exchange chromatography as previously described [20,21].
Granzymes were active as determined by small synthetic
chromogenic substrates and their cleavage potential of macromo-
lecular substrates (data not shown). Protein concentrations were
measured by the method of Bradford.
VWF cleavage assays
Cleavage of VWF was performed either in solution or coated
onto a plastic plate. For immobilized VWF, purified plasma VWF
(2 mg/well) in 100 mL of PBS was incubated overnight at 4uCi na
Maxisorp 96-well plate (Nunc, Roskilde, Denmark). Wells were
washed three times with PBS and treated with the various purified
recombinant granzymes in 50 mL of Tris-buffered saline (TBS)
(20 mM Tris, 150 mM NaCl, pH 7.4) for 1 hour at 37uC. VWF
cleavage in solution was performed with indicated concentrations
of VWF and granzymes in either TBS or 5 mM Tris-HCl, pH7.4.
The incubations were stopped by adding reducing Laemmli
sample buffer. Samples were resolved on 6% SDS-PAGE gels and
transferred to a PVDF membrane (Millipore). The VWF cleavage
products were visualized using a HRP-conjugated anti-VWF
antibody (Dako Glostrup, Denmark). For determination of the
GrM cleavage site, the VWF cleavage product was isolated form
the PVDF membrane, which was stained with Coomassie Brilliant
Blue. N-terminal sequencing (Edman degradation) was outsourced
to Eurosequence (Groningen, The Netherlands).
VWF multimer analysis
Purified plasma VWF (2 mg/mL) was incubated with indicated
concentrations of GrM, GrB, GrM-SA, and GrB-SA in 5 mM
Tris (pH7.4) for 1 hour at 37uC. VWF multimers were separated
by electrophoresis using a 1% stacking and 2% running separating
SDS agarose gel. Subsequently, proteins were transferred to a
PVDF nylon membrane, and the multimers were detected using
anti-human VWF peroxidase-labeled antibody (Dako). The
peroxidase label was visualized by incubation with 0.5 mg/mL
diamino benzidine, 0.3 mg/mL CoCl2, 0.2 mg/mL NiSO4 and
0.02% H2O2 in PBS.
VWF activation factor- Purified plasma VWF (2 mg/mL) was
incubated with GrB, GrM, or buffer only in 5 mM Tris (pH7.4) at
37uC for 1 hour and active VWF was detected by immunosorbent
assay. The VWF activation factor was determined by measuring
the levels of activated VWF that recognizes the active, GPIba
binding conformation by using the AU/VWFa-11 llama-derived
nanobody, as described by Hulstein et al. [22] The VWF activation
factor was calculated by dividing the absorbance slope of a sample
to the slope of the corresponding standard sample (normal plasma
from a pool of more than 150 adult donors served as standard, also
referred to as normal pool plasma, NPP) and correct them for
VWF levels.
VWF ristocetin cofactor assay
Purified plasma VWF (15 mg/mL) was incubated for 1 hour at
37uC with purified GrM, GrM-SA, or GrB in 5 mM Tris (pH7.4).
VWF ristocetin cofactor activity (VWF:RCof) was determined
using the BC von Willebrand reagent (Dade Behring Marburg
GmbH, Marburg, Germany) on the BCS apparatus according to
the manufacturer’s instructions.
Platelet aggregation assay
Blood from healthy donors was collected in 3.8% Tri-
sodiumcitrate. The donors had not taken any aspirin or other
non-steroidal anti-inflammatory drugs in the previous 2 weeks.
Platelet-rich plasma (PRP) was prepared by centrifugation at 160 g
for 15 min at room temperature. The washed platelets were
prepared as described previously [23]. Washed platelet suspension
was further diluted in HEPES-Tyrode buffer (pH7.3) to a platelet
count of 200610
9/L (20,000/mL) and used in a ristocetin-induced
aggregation assay. Purified VWF (6 mg/mL) was incubated with
indicated concentration of GrB or GrM at 37uC for 1 hour. The
incubation product (250 mL) was added to 250 mL of platelet
suspension. Platelet aggregation was induced by adding 1.5 mg/
mL ristocetin (DiaRistin, DiaMed, Switzerland).
VWF-collagen binding assay
Purified VWF (1 mg/mL) was incubated with indicated
concentration of GrB, GrB-SA, GrM or GrM-SA in 5 mM Tris
buffer (pH 7.4) at 37uC for 1 hour. Subsequently, the incubation
product was added to a well coated with collagen type III (Sigma)
(0.1 mg/mL) in 100 mL PBS in a costar 96-wells plate by
centrifugation. The VWF-collagen binding assay was carried out
as described previously [24].
VWF-FVIII binding assays
For immunosorbent assay, a 96 wells ELISA plate was coated
with 10 mg/mL recombinant FVIII (Advate, Baxter AG, Austria)
in 100 mL/well TBS, 10 mM CaCl2, pH 7.4, overnight at 4uC.
The plate was washed three times (TBS, 0.1% Tween, 10 mM
CaCl2) and blocked with TBS, 3% BSA, 0.1% Tween, 10 mM
CaCl2 at 37uC for 1 hour. Meanwhile, purified plasma VWF
(1 mg/mL) was pre-incubated with indicated concentration of
GrB, GrB-SA, GrM or GrM-SA in 5 mM Tris, pH 7.4 at 37uC
for 1 hour. Cleaved VWF (10 mL) was diluted 106 in TBS, 3%
BSA, 0.1% Tween, 10 mM CaCl2 and added to the well for
2 hours at 37uC. After washing the plate three times with TBS,
0.1% Tween, 10 mM CaCl2, bound VWF was detected with a
HRP-conjugated anti-VWF antibody for 30 minutes at 37uC. For
immunoprecipitation analysis, VWF (30 ng) was pre-incubated in
the presence or absence of GrM (100 nM) or GrM-SA (100 nM)
in 5 mM Tris, pH7.4 for 1 hour at 37uC, followed by incubation
with purified FVIII heterodimer (50 nM) (Advate, Baxter) in TBS,
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subsequently incubated with ProtA/G sepharose (25 mL) (Thermo
Scientific) in TBS, 10 mM CaCl2, which was pre-treated with
anti-VWF antibody (300 mg) for 2 hours at room temperature and
blocked in TBS, 10 mM CaCl2, 1% BSA for 30 minutes at room
temperature. Samples were resolved in Laemmli sample buffer
and subjected to SDS-PAGE (7.5%) and Western blotting, using
polyclonal antibodies against VWF (Dako Glostrup, Denmark)
and FVIII (Affinity Biologicals NC).
Plasma measurements in patients with meningococcal
disease
Between 2002 and 2008 from 37 patients with meningococcal
disease were admitted to our pediatric intensive care unit (PICU).
From 31 of these patients plasma was available for analysis.
Informed consent was given for each patient by the parents and
the study was approved by the local ethics committee and
performed according to local guidelines. Diagnosis of meningo-
coccal disease was made based on positive culture of blood,
cerebrospinal fluid (CSF) or skin biopsy, or typical presentation.
All isolated meningococci were group B. Septic shock was defined
according to the consensus conference definitions for sepsis and
organ dysfunction in pediatrics [25]. All patients received
prompt antibiotic treatment (ceftriaxone) and dexamethasone
(460.15 mg/kg) during the first 3 days after admission or until
discharge from the PICU. Additional blood samples were collected
approximately one year after acute disease from 5 patients that
recovered and were defined in this study as healthy controls.
Plasma samples were anti-coagulated with sodium citrate and were
stored at 280uC prior to use. VWF antigen measurement and
other clinical characteristics were described previously [16]. FVIII
measurement was performed with Asserachrom kitH according to
the manufacturer’s instructions (Diagnostic Stage, Asnieres,
France). Mouse anti-human GrM monoclonal antibody was raised
as previously described. [26] Patient plasma samples (5 mL) were
resolved on 12% SDS-PAGE gels and transferred to the PVDF
membrane. GrM was detected by mouse anti-human GrM
monoclonal antibody (clone 4A8E11, 1.0 mg/mL), followed by
Goat anti-Mouse HRP-conjugated secondary antibody (Biosource,
CA, US). Protein was visualized by enhanced chemiluminescence
(ECL) (GE Healthcare, Buckinghamshire, UK), bands were
quantified using a densitometer (ImageQuant TL, Amersham
Bioscience), and quantified using a calibration curve of purified
recombinant GrM.
Statistical Analysis
All data were presented as mean and SD and compared using
a T-test, unless otherwise stated. The Spearman correlation
coefficient was calculated to determine the relationship between
two parameters. A p-value ,0.05 was considered to be statistically
significant. The statistical analyses were performed with SPSS
software, version 15.0.
Figure 1. GrM cleaves VWF. (A) Purified plasma VWF (5 mg/mL) was incubated with various purified recombinant granzymes (300 nM) in TBS for
1 hour at 37uC and analyzed by immuno blot, using an antibody against VWF. Mature VWF and VWF cleavage fragments (*) are indicated by the
arrows. (B) Purified plasma VWF (2 mg/well) was immobilized onto plastic and incubated with various purified recombinant granzymes (300 nM) in
TBS for 1 hour at 37uC and analyzed by immuno blot, using an antibody against VWF. (C) Purified plasma VWF (5 mg/mL) was incubated with different
concentrations of GrM (0–800 nM) or GrM-SA (800 nM) in TBS for 4 hours at 37uC and analyzed by immuno blot, using an antibody against VWF. (D)
Purified plasma VWF (2 mg/well) was immobilized onto plastic and incubated with GrM (0–800 nM) or GrM-SA (800 nM) in TBS for 1 hour at 37uC and
analyzed by immuno blot, using an antibody against VWF. (E) Purified plasma VWF (5 mg/mL) was incubated with GrM (100 nM) for 1 hour at 37uCi n
Tris (pH 7.4) in the presence or absence of increasing concentrations of NaCl (0–600 mM) and analyzed by immuno blot, using an antibody against
VWF. (F) GrM, GrB, and ADAMTS13 cleavage sites in VWF are schematically indicated. Data are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0024216.g001
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GrM cleaves VWF
ADAMTS13 and GrB cleave VWF only when the specific
cleavage sites are exposed in the VWF A2 domain [27–29]. In vitro
this denaturating conformational change can be induced by
immobilization of VWF [12]. To investigate whether human
granzymes other than GrB cleave VWF, we incubated all purified
human granzymes with purified human plasma-derived VWF
under soluble (Tris-buffered saline) (Fig. 1A) and immobilized
conditions (Fig. 1B). As expected, GrB cleaved immobilized VWF
more efficiently as compared with soluble VWF [12]. Interestingly,
GrM cleaved both soluble and immobilized VWF with the
concomitant appearance of a similar VWF cleavage fragment that
differs from those induced by GrB (Fig. 1A,B). This suggests that
GrM cleaves both soluble and immobilized VWF at the same site
at a different position than GrB. GrA, GrH, and GrK did not
cleave VWF under these conditions (Fig. 1A,B). All granzymes
were catalytically active as determined by small synthetic
substrates and by verifying cleavage of specific macromolecular
granzyme substrates (data not shown). To further characterize
VWF cleavage by GrM, purified VWF was incubated with
different concentrations of GrM and the catalytically inactive GrM
mutant (GrM-SA) as a control. GrM cleaved VWF in a
concentration-dependent manner under both soluble (Fig. 1C)
and immobilized (Fig. 1D) conditions, as illustrated by the
progressive disappearance of the full-length VWF protein band
(250 kDa) and the appearance of the specific 220 kDa cleavage
fragment. GrM-SA did not cleave VWF, indicating that VWF
cleavage by GrM fully depends on the catalytic activity of the
protease (Fig. 1C,D). Another method to induce a conformational
change of VWF in vitro is by removal of salt [28,30]. The efficiency
of VWF cleavage by GrM was inhibited by increasing the salt
concentration and was improved by lowering the NaCl concen-
tration, which coincided with the appearance of the 220 kDa
VWF cleavage fragment (fig. 1E). Finally, N-terminal sequencing
of this cleavage fragment revealed that GrM cleaved VWF in its
D3 domain after Leu
276, within the sequence
273KVPLQDSSP
280
(Fig. 1F).
GrM does not affect VWF multimerization
In vivo, all known VWF proteases regulate VWF activity by
cleaving large multimers into less pro-hemostatic forms [6]. To
investigate the effects of GrM on VWF multimerization pattern,
purified VWF was incubated with several concentrations of GrM
and VWF multimers were visualized by electrophoresis (Fig. 2).
Whereas increasing concentrations of GrM gradually cleaved
VWF (Fig. 2A), this cleavage did not significantly affect VWF
multimerization, measured in four separated experiments (Fig. 2B).
As a positive control, GrB cleaved VWF and showed a complete
disappearance of the VWF multimerization pattern (Fig. 2). GrM-
SA neither cleaved VWF nor affected VWF mutimer formation.
These data indicate that unlike ADAMTS13 and GrB, no
significant change in VWF multimerization is observed following
treatment with GrM.
GrM does not affect VWF platelet binding and platelet
aggregation
Another important characteristic of VWF is its binding to the
GPIba receptor expressed on platelets, thereby facilitating the
binding of platelets to the injured vessel wall. First, with a specific
assay using our AU/VWFa-11 llama-derived nanobody we are
able to detect active VWF in its platelet-binding conformation
[31], allowing us to determine which proportion of VWF is able to
bind to GPIba receptor. GrM and GrB were incubated with VWF
and cleaved VWF was subsequently incubated with the AU/
VWFa-11 antibody. This analysis showed that the VWF activation
factor was not affected by GrM cleavage as compared to control,
whereas GrB inhibited the VWF activation factor for about 70%
(Fig. 3A). Second, incubation of VWF with various concentrations
of GrM under similar conditions did not decrease the VWF
ristocetin cofactor activity, whereas GrB-treated VWF was clearly
affected (Fig. 3B). Instead, GrM slightly but statistically signifi-
cantly increased VWF ristocetin cofactor activity. Finally, purified
VWF was pretreated with various concentrations of GrB or GrM
and subsequently incubated with washed isolated platelets to
measure platelet aggregation. The aggregation curves of the GrM-
pretreated VWF were similar to the VWF without added
granzyme in multiple donors (Fig. 3C). As expected, GrB dose-
dependently inhibited platelet aggregation (Fig. 3D). These data
indicate that GrM neither affects VWF platelet binding nor
platelet aggregation.
GrM slightly affects VWF collagen binding activity
The effect of granzymes on collagen binding was investigated,
using an immunosorbent assay. Collagen binding was almost fully
abolished after treatment of VWF with GrB (Fig. 4) and following
pre-incubation with the anti-VWF blocking antibody RU5 (data
not shown). Pre-treatment of VWF with GrM resulted in a minor,
but statistically significant, dose-dependent decrease in collagen
binding as compared to control GrM-SA (Fig. 4, p=0.02).
Maximal decrease in collagen binding was achieved after
Figure 2. GrM does not affect VWF multimerization. Purified
plasma VWF (2 mg/mL) was incubated with indicated concentrations of
GrM, GrB, GrM-SA and GrB-SA in Tris (pH 7.4) for 1 hour at 37uC. (A)
Samples analyzed at 6% SDS-PAGE and Western blot, using an antibody
against VWF. Mature VWF and VWF cleavage fragments (*) are indicated
by the arrows. (B) Samples were separated at a SDS agarose gel and
multimers were visualized on blot. Data are representative of at least
three independent experiments.
doi:10.1371/journal.pone.0024216.g002
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GrM (Fig. 2A). These data indicate that GrM slightly affects VWF
binding to collagen.
GrM destroys the FVIII binding capacity of VWF
VWF tightly binds to and stabilizes coagulation FVIII in
plasma, thereby protecting FVIIII from proteolytic degradation
and prolonging FVIII half-life in vivo [2]. Using an immunosorbent
assay, the FVIII binding capacity of VWF was investigated in the
presence of GrM or GrB (Fig. 5A). A gradual decrease in FVIII
binding up to about 70% was observed after treatment of VWF
with increasing concentrations of GrM (Fig. 5A). Interestingly,
GrB also inhibited VWF binding to FVIII. No effects were
observed with both controls GrM-SA and GrB-SA. VWF cleavage
by both granzymes was verified by immunoblot (Fig. 2A). The
effect of GrM on VWF binding to FVIII was further investigated
by immunoprecipitation analysis (Fig. 5B). Immunoprecipitation
of VWF in the presence of FVIII resulted in the expected pull
down of the FVIII heterodimer (Fig. 5B). In contrast, the VWF-
FVIII interaction was almost completely abolished in the presence
of GrM, but not in the presence of control GrM-SA (Fig. 5B).
FVIII was not cleaved by GrM under these conditions (data not
shown). These data indicate that both GrB and GrM destroy the
FVIII binding capacity of VWF.
Plasma GrM levels positively correlate with VWF/FVIII
ratio in patients with meningococcal septic shock
If GrM cleaves VWF in vivo thereby decreasing the FVIII
binding properties of VWF, one would expect an increased
clearance of FVIII and a concomitant increase of the plasma
VWF/FVIII ratio in the presence of GrM. Currently, it is
unknown whether GrM exists in plasma of healthy subjects or
under certain pathophysiological conditions. Since no quantitative
measurements are available for detecting human GrM in plasma,
we screened our recently developed panel of anti-human GrM
monoclonal antibodies for reactivity on western blot [26].
Monoclonal antibody 4A8E11 worked well in this application
and was specific for GrM, since it did not cross-react with the
Figure 3. GrM does not affect VWF platelet binding affinity. (A) Purified plasma VWF (2 mg/mL) was incubated with GrB (100 nM), GrM
(100 nM), or buffer only in Tris (pH 7.4) at 37uC for 1 hour and active VWF was detected by AU/VWF-A11-based immunosorbent assay. Data represent
the mean +/2 SD of three independent experiments. (B) Purified plasma VWF (15 mg/mL) was incubated for 1 hour at 37uC with various
concentrations of GrM (0–100 nM), GrM-SA (100 nM), or GrB (100 nM) in Tris (pH 7.4) and VWF ristocetin cofactor activity was determined. Data
represent the mean +/2 SD of three independent experiments. (C) Purified plasma VWF (6 mg/mL) was treated with GrM (0–600 nM) or buffer only in
Tris (pH 7.4) for 1 hour at 37uC and subsequently incubated 1:1 with washed platelets (5610
7 platelets/mL). Platelet aggregation was induced by the
addition of ristocetin (1.5 mg/mL). (D) Purified plasma VWF (6 mg/mL) was treated with GrB (0–600 nM) or buffer only in Tris (pH 7.4) for 1 hour at
37uC and subsequently incubated 1:1 with washed platelets (5610
7 platelets/mL). Platelet aggregation was induced by the addition of ristocetin
(1.5 mg/mL). Data are representative of at least four independent experiments with four different donors.
doi:10.1371/journal.pone.0024216.g003
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we have demonstrated that plasma levels of GrB are markedly
increased in patients with meningococcal septic shock [16]. With
our semi-quantitative western blot, we measured plasma levels of
GrM in these patients and controls. No GrM could be detected in
plasma of control patients and in patients without septic shock.
Interestingly, in part of the meningococcal septic shock patients we
could detect elevated levels of plasma GrM, which migrated at the
expected molecular weight of 28 kDa (Fig. 6A). Next, we
measured VWF and FVIII plasma levels and calculated the ratio
between them. Normally, when VWF levels increase, FVIII levels
increase to the same extent and would give a ratio of 1 (when both
are expressed in percentage). In patients with septic shock and
positive levels of GrM as quantified from western blot band
intensities, the VWF/FVIII ratio was increased as compared to the
other groups and controls (Fig. 6B, p,0.05). The VWF/FVIII
ratio also correlated positive with the amount of GrM
detected in GrM-positive meningococcal septic shock patients
(Rspearman=0.92, p,0.001, Fig. 6C). These data indicate that
elevated plasma GrM is detected in meningococcal septic shock
patients and that its levels positively correlate with the VWF/
FVIII ratio, suggesting that GrM affects the FVIII binding
capacity of VWF in these patients.
Discussion
The granule-exocytosis pathway is the main mechanism by
which cytotoxic lymphocytes kill target cells [13]. In human, five
granzymes (GrA, GrB, GrH, GrK and GrM) are known to trigger
cell death, of which GrA and GrB have been best studied. For
GrA, GrB, and GrK, it has been demonstrated that they also exist
extracellularly where they have been postulated to play a role in
extracellular matrix degradation (GrB) [14,15,18,32,33] or pro-
inflammatory cytokine release (GrA) [34]. In this study, we have
shown for the first time that GrM also exists extracellularly in
plasma of patients with meningococcal disease (Fig. 6). We found
that GrM efficiently cleaves plasma-derived VWF. It has been well
established that VWF activity in vivo is regulated by ADAMTS13
and potentially other proteases, including GrB and some leukocyte
proteases [10,12]. In contrast to these proteases that cleave VWF
only when it is artificially unfolded or presented as a matrix, GrM
cleaved plasma-derived VWF under both soluble and denatured
Figure 4. GrM slightly affects VWF binding to collagen. Purified
plasma VWF (1 mg/mL) was incubated with indicated concentrations of
GrB, GrB-SA, GrM, or GrM-SA in Tris (pH 7.4) for 1 hour at 37uC. Samples
were assessed for collagen binding, using an immunosorbent assay.
Data represent the mean +/2 SD of three independent experiments.
GrM (25 nM) versus GrM-SA (25 nM), p=0.02; GrB (25 nM) versus GrB-
SA (25 nM), p,0.001.
doi:10.1371/journal.pone.0024216.g004
Figure 5. GrM disrupts FVIII binding to VWF. (A) Purified plasma VWF (1 mg/mL) VWF was incubated with indicated concentration of GrM, GrB,
GrM-SA or GrB-SA in Tris (pH 7.4) for 1 hour at 37uC and subsequent FVIII binding was assessed in an ELISA setup. Data represent the mean +/2 SD of
three independent experiments. GrM (25 nM) versus GrM-SA (25 nM), p=0.009; GrB (25 nM) versus GrB-SA (25 nM), p=0.009. (B) VWF (30 ng) was
pre-incubated in the presence or absence of GrM (100 nM) or GrM-SA (100 nM) in 5 mM Tris (pH 7.4) for 1 hour at 37uC, followed by incubation with
purified FVIII heterodimer in TBS, 10 mM CaCl2 for 2 hours at 37uC. Protein mixtures were immunoprecipitated by ProtA/G sepharose pre-treated
with anti-VWF antibody. Samples were analyzed by Western blotting, using antibodies against VWF and FVIII heterodimer. Full-length VWF, its GrM-
cleaved form, and the FVIII heavy chain (HCh) and light chain (LCh) are indicated by the arrows. IP, immunoprecipitation; WB, Western blot. Data are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0024216.g005
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VWF and no decrease in pro-hemostatic platelet aggregation
ability of VWF was observed (Figs. 2–3). Instead, GrM is the first
protease identified so far that cleaves VWF in its FVIII binding
site, thereby specifically destroying the binding of VWF to FVIII in
vitro (Fig. 5). In meningococcal septic patients, we found increased
plasma GrM levels that positively correlated with an increased
plasma VWF/FVIII ratio in vivo (Fig. 6). Our data indicate that,
next to its intracellular role in triggering apoptosis, extracellular
GrM could play a physiological role in controlling blood
coagulation by determining plasma FVIII levels via proteolytic
processing of its carrier VWF. Together with previous findings
that GrB cleaves fibrinogen and VWF thereby helping to control
localized coagulation [12], our results point to an important cross-
talk between immune and coagulation systems.
Many proteases have been identified that cleave VWF within or
near a hotspot region in its A2 domain, including ADAMTS13,
GrB, and several leukocyte proteases [10,12,35]. Interestingly,
GrM cleaved VWF outside this hotspot region in the D3 domain,
thereby removing a relatively small N-terminal region from the
mature VWF molecule. GrM cleavage occurred after P1-Leu at
position 276 in the sequence Lys-Val-Pro-Leu-Q-Asp-Ser-Ser-
Pro. These P1 (i.e., Leu) and P2–P4 subsite amino acids (i.e., Lys-
Val-Pro) are completely consistent with previous advanced
positional scanning of GrM substrate specificity with tetra-peptide
libraries (PS-SCL) [36]. This analysis has revealed that Lys-Val-
Pro-Leu is the most optimal P4-P1 sequence for human GrM
cleavage. Since the pro-hemostatic activity of VWF is largely
dependent on regions outside the D3 domain, one would expect
that GrM-cleaved VWF retains its pro-hemostatic activity. Indeed,
although GrM slightly affected VWF-collagen binding, GrM did
not affect VWF multimerization or platelet binding and platelet
aggregation (Figs. 2–4). Interestingly, VWF:RCo activity was
slightly, but statistically significantly, elevated following GrM
treatment (Fig. 3B). This is in agreement with a previous
observation showing that removal of the VWF amino acids 1–
272 increases the affinity of VWF for the GPIba receptor [37]. We
did not observe this effect in the platelet aggregation assay, but this
could be due to a lower sensitivity of this assay. Cleavage after Leu
at position 276 by GrM almost fully destroyed the ability of VWF
to bind to FVIII (Fig. 5). This is compatible with an important
FVIII binding site in the VWF D3 domain [38,39]. GrB cleaves
VWF in the A2 domain hotspot and not only abolishes VWF
multimerization and platelet aggregation, but also impaired FVIII
binding. Whether VWF-cleaving proteases other than GrM and
GrB affect the VWF-FVIII interaction remains unknown.
The study of the physiological relevance of VWF-cleaving
proteases in vivo is hampered by the lack of adequate mouse
models. First, ADAMTS13-deficient mice do not develop TTP,
indicating interspecies differences in VWF regulation [40].
Second, mouse granzymes display different substrate specificities
than human granzymes [41,42]. Finally, the GrM cleavage site
(KVPL) is not conserved in mouse VWF and purified recombinant
mouse GrM does not cleave mouse VWF in plasma (unpublished
results). Therefore, we studied the physiological relevance of GrM
in VWF biology in humans. As we have previously described for
GrB [16], we demonstrated in the current study that also GrM is
elevated in patients with septic shock (Fig. 6). Since GrB does not
cleave VWF in its soluble conformation [12], it seems likely that if
granzymes cleave VWF in plasma this will be mediated by GrM.
However, it remains a question whether GrM levels in plasma are
sufficient to cleave VWF in vivo. The exact GrM concentration in
plasma could not be determined because no GrM ELISA is
currently available. Since GrM is elevated in septic shock patients
and abolishes VWF binding to FVIII, one would expect an
increase in the VWF/FVIII ratio in these patients if GrM cleaves
VWF in vivo. Indeed, an increase of the VWF/FVIII ratio was
observed in septic shock patients that positively correlated with the
Figure 6. Plasma GrM and VWF/FVIII ratios positively correlate in patients with meningococcal disease. (A) Representative example of
GrM in plasma of patients with meningococcal disease without shock (1) and with shock (2–5), using immunoblotting with a monoclonal antibody
against GrM. (B) VWF and FVIII levels in plasma were determined by ELISA and chromogenic activity, respectively. VWF/FVIII ratios were determined in
meningococcal shock patients with or without detectable plasma GrM, patients with meningococcal disease without shock, and healthy controls. P
values are indicated. (C) VWF/FVIII ratios are plotted against plasma GrM levels, as quantified by western blot. Rspearman=0.92, p,0.001.
doi:10.1371/journal.pone.0024216.g006
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thereof remains to be determined, this is compatible with our
hypothesis that GrM in plasma cleaves VWF and thereby
negatively influences plasma levels of FVIII. Direct evidence for
the cleavage of VWF by GrM and the concomitant regulation of
FVIII levels in human plasma, however, will require a VWF
mutant that is resistant to GrM proteolysis. Currently, this is not
possible since there is no human patient known with a mutation in
VWF at the GrM-cleavage site and also no human GrM-
deficiencies have been described.
Modulation of granzyme activity in vivo could potentially have
therapeutic implications. Increased consumption of active VWF
together with platelets causes disseminated intravascular coagula-
tion and subsequently bleeding complications, as we also have
observed in our meningococcal patients [16]. Because GrB cleaves
and destroys VWF pro-hemostatic activity in vitro [12,16], this
study], it will be of future interest to study whether GrB also
inactivates VWF in vivo and thereby can be used as replacement for
ADAMTS13 in diseases like TTP and/or during infection (where
also lower ADAMTS13 levels are observed). Indeed, a first
response by the body is to increase GrB levels in meningococcal
patients [16,43], but probably this is not enough to stop the
massive coagulation activation in these patients by itself. Since
GrM specifically targets the FVIII-binding capacity of VWF
(Fig. 5), therapeutic administration of GrM concentrates in plasma
may potentially lower plasma FVIII levels in patients with high
FVIII and a concomitant tendency for developing thrombosis,
while leaving the pro-hemostatic function of VWF intact. On the
other hand, specific synthetic granzyme inhibitors could be a
promising intervention strategy against bleeding complications in
pathological disorders in which plasma granzymes are markedly
elevated.
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